Exscientia appoints Oxford Innovation Sciences founder and ex-Lansdowne CEO as Deputy Chairman

pharmafile | December 11, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alex Snow, Exscientia, appointment 

Exscientia, an Oxford-based drug design firm which has made headlines this year for its collaboration with GlaxoSmithKline to leverage its own proprietary AI-based drug discovery platform, has announced the appointment of Alex Snow to its Board of Directors as its Deputy Chairman.

Snow brings a rich background in investment, banking and entrepreneurship spanning 20 years to the role. He is the founder of Oxford Sciences Innovation (OSI) and is responsible for raising over £600 million commercialise science originating at the University of Oxford.

Previous to his time with OSI, Snow served as CEO of hedge fund Lansdowne Partners, and is also the founder and ex-CEO of UK investment banking and securities firm Evolution Group.

“We are delighted to welcome Alex to Exscientia. Alex brings deep investor knowledge and unique entrepreneurial skills to the Board. He has a passion for translating-cutting edge science into long-term, tangible value,” commented Andrew Hopkins, Chairman and CEO of Exscientia. “The deep and active commitment Alex has shown to the Company and the energy he brings to the role of Deputy Chairman will bring immense value. We are confident that his extensive experience in the investment community and wide networks will be invaluable in supporting the Company’s strategy for growth. We have made great progress in 2017, having announced collaborations with GSK, Sanofi and a significant investment from Evotec; with Alex joining us, we look forward to an exciting year in 2018.”

Snow himself remarked: “Exscientia is a truly exciting company with the potential to be a game-changer in the pharma industry, as a tech company that discovers drugs. There is growing realisation of the disruptive potential of AI in pharma, and Exscientia is leading the field. With the successes so far achieved, we are beginning to see exciting evidence of acceleration of the discovery of new medicines through application of its unique AI platform. The Company has signed some impressive deals to date and is poised to move to the next phase of its development. I am very much looking forward to making my contribution to building a great company.”

Related Content

Exscientia enters AI drug discovery collaboration with Merck KGaA

Exscientia has announced a new collaboration with Merck KGaA, Darmstadt, Germany, with a focus on …


Exscientia to collaborate with EQRx on drug development

Exscientia and EQRx have announced a strategic research and development collaboration agreement aiming to substantially …

Exscientia launch trial of third AI-designed molecule

Exscientia has launched Phase I trials in the US of DSP-0038 for the treatment of …

Latest content